Researchers from Tokyo University of Science and Kyoto University have uncovered a key immune mechanism behind the atopic march, in which allergies that begin in the skin progress to affect the whole body. They found that IL-13 activates specialized immune cells that trigger the production of allergy-causing antibodies. The discovery could help researchers develop new ways to prevent severe allergic reactions and stop allergies from becoming more serious. 

A research team led by Dr. Masaki Arata and Professor Toshihiko Fujimori at Japan’s National Institute for Basic Biology investigated how longitudinal oviduct epithelial folds affect oocyte transport. Using mutant mice with disrupted fold architecture due to reduced VANGL1 protein, they discovered that directional ciliary beating remained largely intact, and the mice remained fertile. Tracking fluorescent beads revealed that transport in mutants was slower and less direct. The findings demonstrate that while longitudinal folds of the oviduct are not strictly essential for moving eggs to the uterus, they serve to optimize transport speed, stability, and overall efficiency.

A comprehensive new review article highlights the growing importance of the MYH9 gene as a central player in both cancer biology and inherited genetic conditions, offering fresh perspectives on its potential as a therapeutic target.

A comprehensive new review highlights the growing importance of FOXK2, a versatile transcription factor, in shaping cancer behavior and influencing clinical outcomes across a wide range of tumor types. The article brings together emerging knowledge to clarify how this gene functions in cancer and why it is attracting increasing attention as a potential diagnostic and prognostic marker.

ARDD 2026 has announced that Fiona Marshall, President of Biomedical Research at Novartis, will deliver a featured presentation, "Reimagining Drug Discovery Through the Lens of Aging Biology," at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at Harvard University's David Rubenstein Treehouse in Boston. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

ARDD 2026 has announced that Fiona Marshall, President of Biomedical Research at Novartis, will deliver a featured presentation, "Reimagining Drug Discovery Through the Lens of Aging Biology," at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.